Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
XELODA has been on the market since 1998, when it was the first oral chemotherapy approved by the FDA for the treatment of metastatic Breast Cancer. In 2001, it became the first oral chemotherapy approved for the treatment of metastatic Colorectal Cancer. It received FDA approval for the treatment of Dukes’ C (Stage III) Colon Cancer in 2005.
